New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association 2021 Virtual Congress, including: Celltrion, Crispr, Daiichi Sankyo, Debiopharm, Janssen, Kite, Omeros, TG, Vertex, X4.
Beigene Ltd. unveiled positive interim results from its Alpine phase III trial comparing its small-molecule BTK inhibitor, Brukinsa (zanubrutinib), to Abbvie Inc.’s Imbruvica (ibrutinib), lending validity to one of the company’s most important development programs.
New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association 2021 Virtual Congress, including: Abbvie, Acceleron, Agios, Alexion, Aptose, Autolus, Beigene, Bergenbio, Bluebird, BMS, Caelum, Celyad, Constellation, Curis, Editas, Equillium, Forma, Genentech, Global Blood, Imago, Imara, Immunicum, Keros, Menarini, Mustang, Novartis, Oryzon, Protagonist, Ryvu.
New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association's Annual Congress, including: ADC, Agios, Alx, Apellis, Aprea, Aptose, Astrazeneca, Autolus, Beigene, Bluebird, Constellation, Crispr, Editas, Forma, Imago, Imara, Geron, Keros, Kiadis, Omeros, Oryzon, Principia, Sierra Oncology, Takeda, TG, Tolero, Vertex, X4.
RSS